SecBot SecBot
8-K ·Filed Apr 27, 2026

ERAS

Erasca, Inc.
MIXED
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-179214
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ◆ Mixed

Monitor the upcoming webcast for clinical data strength, but assess whether the results justify the legal risk. Watch for any escalation in the RevMed dispute, including a formal lawsuit filing or preliminary injunction motion, which could severely impact ERAS-0015's development timeline and valuation.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.15
T+0 close · Apr 27, 2026 · via day close
Latest settled
+1.88%
T+60 · $19.51
Vs SPY
−2.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $19.15entry
  2. T+1 · 7mo ago −48.30%α −47.82% · $9.90
  3. T+5 · 7mo ago −47.05%α −47.45% · $10.14
  4. T+20 · 6mo ago −39.95%α −44.90% · $11.50
  5. T+60 · 4mo ago +1.88%α −2.90% · $19.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca disclosed preliminary Phase 1 data for its RAS-targeting drug ERAS-0015 while simultaneously revealing a patent and trade secret infringement claim from Revolution Medicines. The litigation threat over a key asset creates significant near-term uncertainty despite the positive clinical update.

Key Facts

  • Erasca announced a webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue for RAS-mutant solid tumors.
  • Revolution Medicines (RevMed) alleged that ERAS-0015 infringes its U.S. Patent No. 12,409,225 under the doctrine of equivalents.
  • RevMed also claimed Erasca is liable for misappropriation of trade secrets related to ERAS-0015 and accused the company of making deceptive comparative statements.
  • RevMed demanded Erasca cease all development and commercialization activities for ERAS-0015 in the U.S. outside the Hatch-Waxman safe harbor.
  • Erasca stated it believes the allegations are without merit and intends to contest them vigorously.

Financial Impact

High risk to future revenue potential of ERAS-0015; potential for significant legal costs, injunction, or royalty payments if litigation escalates.

pipeline valueR&D expenseslegal expensesmarket valuation

Risk Factors

  • ERAS-0015 development could be halted or delayed by litigation.
  • Potential for material financial liability through damages or royalties if infringement is found.
  • Reputational damage from trade secret allegations and comparative claims.
  • Clinical data may be overshadowed by legal overhang, limiting positive market reaction.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-179214
Document: 0001193125-26-179214-index-headers.html0001193125-26-179214
Document: 0001193125-26-179214-index.html0001193125-26-179214
Document: 0001193125-26-179214.txt0001193125-26-179214

Track record

26 reports on ERAS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026